A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles

Basit Öğe Kaydı
dc.contributor.authorŞekerdağ, Emine
dc.contributor.authorLüle, Sevda
dc.contributor.authorBozdağ Pehlivan, Sibel
dc.contributor.authorÖztürk, Naile
dc.contributor.authorKara, Aslı
dc.contributor.authorKaffashi, Abbas
dc.contributor.authorVural, İmran
dc.contributor.authorIşıkay, İlkay
dc.contributor.authorYavuz, Burçin
dc.contributor.authorKarlı Oğuz, Hatice Kader
dc.contributor.authorSöylemezoğlu, Figen
dc.contributor.authorGürsoy Özdemir, Yasemin
dc.contributor.authorMut, Melike
dc.date.accessioned2019-05-10T09:39:38Z
dc.date.available2019-05-10T09:39:38Z
dc.date.issued2017
dc.departmentHitit Üniversitesi, Sungurlu Meslek Yüksekokulu, Tıbbi Hizmetler ve Teknikler Bölümü
dc.description.abstractNew drug delivery systems are highly needed in research and clinical area to effectively treat gliomas by reaching a high antineoplastic drug concentration at the target site without damaging healthy tissues. Intranasal (IN) administration, an alternative route for non-invasive drug delivery to the brain, bypasses the blood-brainbarrier (BBB) and eliminates systemic side effects. This study evaluated the antitumor efficacy of farnesylthiosalicylic acid (FTA) loaded (lipid-cationic) lipid-PEG-PLGA hybrid nanoparticles (HNPs) after IN application in rats. FTA loaded HNPs were prepared, characterized and evaluated for cytotoxicity. Rat glioma 2 (RG2) cells were implanted unilaterally into the right striatum of female Wistar rats. 10 days later, glioma bearing rats received either no treatment, or 5 repeated doses of 500 mu M freshly prepared FTA loaded HNPs via IN or intravenous (IV) application. Pre-treatment and post-treatment tumor sizes were determined with MRI. After a treatment period of 5 days, IN applied FTA loaded HNPs achieved a significant decrease of 55.7% in tumor area, equal to IV applied FTA loaded HNPs. Herewith, we showed the potential utility of IN application of FTA loaded HNPs as a non-invasive approach in glioblastoma treatment.
dc.identifier.citationSekerdag, E., Lüle, S., Pehlivan, S. B., Öztürk, N., Kara, A., Kaffashi, A., ... & Söylemezoğlu, F. (2017). A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles. Journal of Controlled Release, 261, 187-198.
dc.identifier.doi10.1016/j.jconrel.2017.06.032
dc.identifier.endpage198en_US
dc.identifier.issn0168-3659
dc.identifier.scopusqualityQ1
dc.identifier.startpage187en_US
dc.identifier.urihttps://doi.org/10.1016/j.jconrel.2017.06.032
dc.identifier.urihttps://hdl.handle.net/11491/742
dc.identifier.volume261en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofJournal of Controlled Release
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDrug Deliveryen_US
dc.subjectFarnesylthiosalicylic Aciden_US
dc.subjectGlioblastomaen_US
dc.subjectHybrid Nanoparticlesen_US
dc.subjectNose-to-Brainen_US
dc.titleA potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu